TABLE 2.
Study designa | TX period | Included patients | Endpoint; timing | Patients with event; infectious events | PCR | Main association | Limitationsb |
---|---|---|---|---|---|---|---|
Cohort80 | 2016 | 71 | Infection leading to medical measure; months 4–12 post-TX | 22; 41 | IH | TTV 1 mo before event–infection | Interim analysis; secondary endpoint |
Cohort74 | 2014–2016 | 221 | Infection leading to medical measure/opportunistic infection + malignancy; <12 mo post-TX | 51; 65 | C | TTV 1 mo post-TX–subsequent event | Two main endpoints; multiple testing; missing information on model design/some major determinants of TTV not included |
Cohort81 | 2015–2016 | 116 | BKV viremia; <12 mo post-TX | 24; 24 | C | NA | Multiple testing; no effect size adjustment |
Cohort75 | 2016–2018 | 274 | Infection leading to medical measure; months 4–12 post-TX | 127; 193 | IH | TTV 1 mo before event–infection | Secondary endpoint |
Case-control82,c | 2011–2016 | 145 | CMV viremia; <4 mo post-TX | 35; 35 | IH | TTV days 0 to 10 post-TX–CMV | Possible selection bias; main analyses include LTX; multiple testing; no effect size adjustment |
Case-control79 | 2012–2014 | 66 | BKV viremia; <2 y post-TX | 50; 50 | C | TTV–BKV month 6 post-TX | Possible selection bias; multiple testing; no effect size adjustment |
Case-control83 | 2014–2016 | 215 | BKV viremia; <12 mo post-TX | 47; 47 | C | TTV 1 mo post-TX–subsequent BKV | No data on subject selection; multiple testing; missing information on model design/some major determinants of TTV not included |
Case-control21 | 2003–2013 | 389 | BKV and CMV viremia; <12 mo post-TX | 182; 105/77d | IH | TTV kinetic–time to infection | CMV secondary endpoint |
The studies are listed according to their design and date of their online publication.
All studies followed a noninterventional and single-center design.
Kidney and liver transplant recipients.
One hundred five BKV and 77 CMV.
BKV, BK polyomavirus; C, commercial; CMV, cytomegalovirus; IH, in-house; LTX, liver transplantation; NA, not available; PCR, polymerase chain reaction; TTV, torque teno virus; TX, transplantation.